Type 2 diabetes. The management of type 2 diabetes.

GUIDELINE TITLE
Type 2 diabetes. The management of type 2 diabetes.

BIBLIOGRAPHIC SOURCE(S)
National Collaborating Centre for Chronic Conditions. Type 2 diabetes. The management of type 2 diabetes. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 May. 49 p. (Clinical guideline; no. 87).

GUIDELINE STATUS
This is the current release of the guideline.

This release updates a previously published guideline: National Collaborating Centre for Chronic Conditions. Type 2 diabetes. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 May. 44 p. (Clinical guideline; no. 66).

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

November 17, 2009 – Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix) and omeprazole (Prilosec/Prilosec OTC) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.

November 3, 2009 – Byetta (exenatide): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency.

September 25, 2009 – Januvia and Janumet (Sitagliptin): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients of revisions to the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) to include information on reported cases of acute pancreatitis in patients using these products.

February 26, 2009 – Reglan (metoclopramide): The U.S. Food and Drug Administration (FDA) notified healthcare professionals that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use.

abrir aquí para acceder al documento NGC AHRQ completo:
Type 2 diabetes. The management of type 2 diabetes.